Valuation: Immunovia AB

Market Cap 12Cr 1.21Cr 1.07Cr 99.13L 90.97L 1.71Cr 116.88Cr 1.74Cr 4.6Cr 57Cr 4.56Cr 4.46Cr 198.67Cr P/E 2026 *
-1.75x
P/E 2027 * -4.38x
Enterprise Value 5.07Cr 52.29L 45.93L 42.71L 39.19L 73.64L 50Cr 74.77L 1.98Cr 25Cr 1.96Cr 1.92Cr 86Cr EV / Sales 2026 *
15.8x
EV / Sales 2027 * 2.53x
Free-Float
89.3%
Yield 2026 *
-
Yield 2027 * -
1 day-32.03%
1 week+16,951.28%
Current month+16,370.59%
1 month+16,507.70%
3 months+15,860.00%
6 months+14,475.34%
Current year+13,658.62%
1 week 0.18
Extreme 0.176
0.32
1 month 0.18
Extreme 0.176
0.32
Current year 0.15
Extreme 0.1544
0.32
1 year 0.15
Extreme 0.1544
0.92
3 years 0.15
Extreme 0.1544
2.78
5 years 0.15
Extreme 0.1544
139.14
10 years 0.15
Extreme 0.1544
292
Manager TitleAgeSince
Chief Executive Officer 53 29/04/2023
Chief Tech/Sci/R&D Officer 55 29/04/2024
Chief Tech/Sci/R&D Officer 54 31/01/2024
Director TitleAgeSince
Director/Board Member 72 09/12/2016
Chairman 69 26/05/2023
Director/Board Member 51 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
-32.03%+16,951.28% - - 1.21Cr
-0.36%-9.20%+15.65%-38.20% 1.55TCr
-7.90%+5.00%-2.15%+85.22% 164.65Cr
-3.20%-7.65%-41.40%-81.82% 109.45Cr
-1.41%-4.66%-38.57%+12.65% 95Cr
-3.39%-5.61%-45.48%-55.97% 61Cr
-2.46%-5.34%-51.05%-59.36% 50Cr
+1.87%+3.51%+39.11%-52.44% 46Cr
+1.52%-3.98%-57.46%-60.92% 37Cr
+0.72%-4.89%-22.14%-36.51% 34Cr
Average -4.66%-3.58%-22.61%-31.93% 239.02Cr
Weighted average by Cap. -1.18%-7.28%+4.35%-30.39%

Financials

2026 *2027 *
Net sales 32L 3L 3L 3L 2L 5L 3.18Cr 5L 12.5L 1.56Cr 12.39L 12.12L 5.4Cr 1.73Cr 17.84L 15.67L 14.57L 13.37L 25.12L 17Cr 25.51L 67.59L 8.44Cr 66.96L 65.51L 29Cr
Net income -9.1Cr -93.82L -82.4L -76.63L -70.32L -1.32Cr -90Cr -1.34Cr -3.56Cr -44Cr -3.52Cr -3.45Cr -153.58Cr -8.2Cr -84.54L -74.25L -69.05L -63.37L -1.19Cr -81Cr -1.21Cr -3.2Cr -40Cr -3.17Cr -3.11Cr -138.39Cr
Net Debt -6.7Cr -69.08L -60.67L -56.42L -51.77L -97.28L -67Cr -98.78L -2.62Cr -33Cr -2.59Cr -2.54Cr -113.08Cr -7.4Cr -76.29L -67.01L -62.32L -57.18L -1.07Cr -73Cr -1.09Cr -2.89Cr -36Cr -2.86Cr -2.8Cr -124.89Cr
Logo Immunovia AB
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Employees
17
Date Price Change Volume

Quarterly revenue - Rate of surprise